Literature DB >> 8923101

Neuroleptic malignant syndrome associated with abrupt withdrawal of anticholinergic agents.

B Spivak1, N Gonen, R Mester, E Averbuch, S Adlersberg, A Weizman.   

Abstract

Neuroleptic malignant syndrome (NMS) is a severe side-effect of neuroleptic treatment. It is usually related to hypodopaminergic activity. A young schizophrenic patient who developed a typical episode of NMS during abrupt withdrawal of long-acting neuroleptic combined with anticholinergic treatment is described. NMS appeared following combined neuroleptic/ anticholinergic withdrawal and responded to procyclidine administration. The appearance of NMS after discontinuation of antidopaminergic treatment seems to be in conflict with the hypodopaminergic theory of this adverse effect. It is suggested that simultaneous withdrawal of both anticholinergic and neuroleptic medications, mainly long-acting neuroleptics, seems to be a risk factor for NMS.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8923101     DOI: 10.1097/00004850-199609000-00009

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  3 in total

1.  Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993-2015.

Authors:  Michael Schneider; Johannes Regente; Timo Greiner; Stephanie Lensky; Stefan Bleich; Sermin Toto; Renate Grohmann; Susanne Stübner; Martin Heinze
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-11-30       Impact factor: 5.270

Review 2.  Recognition of acute illness in people with chronic neurological disability.

Authors:  A M O Bakheit
Journal:  Postgrad Med J       Date:  2006-04       Impact factor: 2.401

3.  Probable case of neuroleptic malignant syndrome following administration of antituberculotic drugs in a chlorpromazine-treated patient.

Authors:  GeumSook Shim; Do-Hyung Kang; Jun Soo Kwon
Journal:  J Korean Med Sci       Date:  2008-08       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.